Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk

Published:2006-02-23 Issue:7 Volume:27 Page:796-801
ISSN:1522-9645
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Deckers Jaap W.,Goedhart Dick M.,Boersma Eric,Briggs Andrew,Bertrand Michel,Ferrari Roberto,Remme Willem J.,Fox Kim,Simoons Maarten L.

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/27/7/796/9626422/ehi809.pdf

Reference30 articles.

1. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Executive summary. Eur Heart J2003;24:1601–1610.

2. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart outcomes prevention evaluation study investigators. N Engl J Med2000;342:145–153.

3. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet2003;362:782–788.

4. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet2005;365:434–441.

5. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med2004;351:2058–2068.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoeconomic issues in stem cell mobilization;Transfusion and Apheresis Science;2023-12

2. Possible pathway for heart failure with preserved ejection fraction prevention and treatment: the angiotensin-converting enzyme inhibitor effect on endothelial function in comorbid patients;Kardiologiia;2022-01-31

3. Preventive implantable cardioverter defibrillator therapy in contemporary clinical practice: need for more stringent selection criteria;ESC Heart Failure;2021-08

4. Long-term Survival in a Spanish Population With Stable Ischemic Heart Disease. The CICCOR Registry;Revista Española de Cardiología (English Edition);2019-10

5. Supervivencia a largo plazo de una población española con cardiopatía isquémica estable: el registro CICCOR;Revista Española de Cardiología;2019-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3